Coherus BioSciences logo
Coherus BioSciences CHRS
$ 1.61 -5.03%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Coherus BioSciences Cash Flow 2011-2026 | CHRS

Annual Cash Flow Coherus BioSciences

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-175 M -241 M -37.4 M 154 M 28.4 M -159 M -200 M -253 M - - - - -

Depreciation & Amortization

3.2 M 3.6 M 3.5 M 2.89 M 3.26 M 3.24 M 3.4 M 3 M 1.87 M 674 K 404 K 221 K -

Accounts Payables

35.2 M 11.5 M 16.2 M 15.2 M 26 M 15.3 M 15.5 M 19.7 M 25.9 M 8.78 M - - -

Accounts Receivables

261 M 110 M 123 M 157 M 142 M - - 1.86 M 1.56 M 2.42 M - - -

Total Inventories

62.6 M 38.8 M 37.6 M 44.2 M 9.81 M 1.66 M - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Coherus BioSciences

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -25.8 M - - - -46.8 M - - - -68.7 M - -141 M - -54 M - 14.9 M - 1.37 M - 121 M 73.7 M 13.5 M - 10.6 M -44.3 M -57 M - -112 M -69.1 M -33.6 M - -170 M -129 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

300 K 300 K 400 K - 400 K 500 K 600 K - 800 K 800 K 900 K - 900 K 900 K 767 K - 900 K 900 K 849 K - 700 K 700 K 607 K - 800 K 700 K 691 K - 800 K 902 K 922 K - 800 K 838 K 865 K - 800 K 729 K 717 K - 636 K 400 K 232 K - 192 K 131 K 116 K - 101 K - - - - - - - - - -

Accounts Payables

24.9 M 37.6 M 40.9 M 28.5 M 21.9 M 76.8 M 38.3 M 35.2 M 37.1 M 29.3 M 23.2 M 11.5 M 9.92 M - 21.1 M 16.2 M 45.7 M 14.6 M 15.5 M 15.2 M 15.2 M 15.2 M 15.2 M 26 M 26 M 26 M 26 M 15.3 M 15.3 M 15.3 M 15.3 M 15.5 M 15.5 M 15.5 M 15.5 M 19.7 M 19.7 M 19.7 M 19.7 M 25.9 M 25.9 M 25.9 M 25.9 M 8.78 M 8.78 M 8.78 M 8.78 M 3.3 M 3.3 M - - - - - - - - - -

Accounts Receivables

9.24 M 5.11 M 60.5 M 111 M 168 M 175 M 252 M 261 M 217 M 141 M 101 M 110 M 91.2 M - 117 M 123 M 136 M 142 M 140 M 157 M 157 M 157 M 157 M 142 M 142 M 142 M 142 M - - - - - - - 26 K 1.86 M 1.86 M 1.86 M 1.86 M 1.56 M 1.56 M 1.56 M 1.56 M 2.42 M 2.42 M 2.42 M 2.42 M 278 K - - - - - - - - - - -

Total Inventories

2.05 M 4.51 M 3.52 M 4.21 M 47.6 M 62.2 M 62 M 62.6 M 66.8 M 64 M 49.4 M 38.8 M 27.7 M - 36.9 M 37.6 M 37.6 M 39.7 M 51.6 M 44.2 M 44.2 M 44.2 M 44.2 M 9.81 M 9.81 M 9.81 M 9.81 M 1.66 M 1.66 M 1.66 M 1.66 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Coherus BioSciences, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Adagene Adagene
ADAG
$ 1.65 7.91 % $ 92.9 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.59 1.99 % $ 8.64 B australiaAustralia
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 66.05 2.3 % $ 8.83 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.52 -16.3 % $ 388 M britainBritain
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Biogen Biogen
BIIB
$ 184.48 -1.67 % $ 26.9 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 102.17 2.32 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
$ 93.52 -1.2 % $ 96.9 B britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.25 1.67 % $ 9.25 B israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 55.71 -0.28 % $ 113 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 207.49 2.22 % $ 5 B danmarkDanmark
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Zai Lab Limited Zai Lab Limited
ZLAB
$ 18.37 -0.97 % $ 18.2 B chinaChina
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 10.84 0.46 % $ 714 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 25.59 -6.54 % $ 1.65 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.22 -4.2 % $ 116 M franceFrance
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 37.35 -0.4 % $ 3.86 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.18 2.02 % $ 2.75 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 55.11 3.49 % $ 4.45 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.17 2.47 % $ 4.65 B schweizSchweiz
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 3.53 -5.75 % $ 231 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 29.43 6.09 % $ 1.43 B usaUSA